Mogamulizumab is a Defucosylated Anti-CCR4 Monoclonal Antibody
C-C Motif Chemokine Receptor 4 (CCR4) is a G-coupled-protein receptor for C-C chemokines. It’s on surface of tumor cells in leukemia and lymphoma patients. For example, adult T-cell leukemia-lymphoma (ATLL), peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL) all expresses CCR-4. Furthermore, leukemia and lymphoma are clinically and...
GR-46611 is a 5-HT1D Receptor Agonist
5-HT1D (5-hydroxytryptamine (serotonin) receptor 1D) is a G protein-linked receptor that activates an intracellular messenger cascade to produce an inhibitory response by decreasing cellular levels of cAMP. Besides, 5-HT1D acts on the central nervous system and affects locomotion and anxiety. Importantly, it also induces vasoconstriction in the brain. Particularly,...
Pirarubicin, an Anthracycline Antibiotics, Acts as a Topoisomerase II Inhibitor
Pirarubicin has widely application in intravesical chemotherapy for bladder cancer, but drug resistance limits its efficacy; the mechanism still needs further exploration. Bladder cancer is the most common malignancy of the urinary tract in China. 75–85% of bladder cancers are grouped as non-muscle invasive bladder tumors. Intravesical chemotherapy...
Saracatinib (AZD0530) is a potent Src Family Inhibitor
Src is a prototypical non-receptor tyrosine kinase. It also includes c-Yes and Fyn. Src transduces signals that control processes involved in cell proliferation, adhesion, and motility. Clinical evidence supports a link between deregulation of Src activity and tumor progression and metastasis. Src over-expression and activation are associated with numerous...
A Potent and Reversible EGFR Inhibitor (E)-AG 99
(E)-AG 99 is a potent and reversible EGFR inhibitor and has potential treatment Bladder cancer. Bladder cancer (BC) is one of common malignancies worldwide. Bladder cancer is any of several types of cancers arising from the tissues of the urinary bladder. The prevalence of EGFR expression in bladder cancer...